Zacks.com on MSN16d
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung CancerGilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...
Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback